IBEX 35
10.882,90 +10,90 (+0,10%) Euro Stoxx 50
4.933,97 +43,36 (+0,89%) Dólar/Euro
1,0794 +0,0067 (+0,63%) Petróleo Brent
83,83 +0,16 (+0,19%) Oro
2.314,60 +5,00 (+0,22%) Bitcoin EUR
56.540,80 +2.245,50 (+4,14%)
Roivant Sciences Ltd. (ROIV)
Antes de la apertura:
Roivant Sciences Ltd.
50 Broadway
7th Floor
London SW1H 0DB
United Kingdom
44 20 7400 3347
https://roivant.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 904
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Matthew Gline | CEO & Director | 1,77M | N/A | 1984 |
| Dr. Eric Venker M.D., Pharm.D. | President & COO | 1,28M | N/A | 1987 |
| Dr. Mayukh Sukhatme M.D. | President, Chief Investment Officer & Director | 1,72M | N/A | 1976 |
| Mr. Richard Pulik | Chief Financial Officer | N/A | N/A | 1979 |
| Ms. Rakhi Kumar | Chief Accounting Officer | N/A | N/A | 1980 |
| Dr. Huafeng Xu Ph.D. | Chief Technology Officer | N/A | N/A | N/A |
| Mr. Jo Chen | General Counsel | N/A | N/A | N/A |
| Ms. Kelly Graff | Head of People | N/A | N/A | N/A |
| Ms. Marianne L. Romeo | Head of Global Transactions & Risk Management | N/A | N/A | 1968 |
| Mr. Alex Gasner | Executive Vice President of Roivant Health | N/A | N/A | N/A |
Descripción
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.
Gobierno corporativo
El ISS Governance QualityScore de Roivant Sciences Ltd., a día 1 de mayo de 2024, es 9. Las puntuaciones base son Auditoría: 8; Tablero: 6; Derechos de los accionistas: 3; Compensación: 10.
